New clinical trial looking for participants to test semaglutide in type 1 diabetes
A new clinical trial investigating the use of semaglutide for type 1 diabetes (T1D) has launched in Sydney and is actively recruiting. The trial, called REducing Cardiometabolic Risk with SEmaglutide in Type 1 diabetes (The RESET1 study) is looking for adults to test whether semaglutide, a medication currently used to treat type 2 diabetes, can improve heart health in people with T1D.
People with T1D are at increased risk of developing heart disease, and it is a common long-term complication of the condition. This is why treatments addressing drivers of poor heart health, such as excess weight, insulin resistance and high blood glucose levels, are urgently needed.
Am I eligible?
The trial is looking for 60 adults aged 25 to 70 years who:
- have a body mass index (BMI) above 25
- have risk factors for heart disease (such as high blood pressure, high cholesterol, or they’re a smoker)
- were diagnosed with T1D at least 2 years ago.
What will the study involve?
Participants will be given semaglutide or a placebo once a week for 26 weeks. The study will include blood and urine tests, body composition and liver scans, and will be conducted at the Garvan Institute of Medical Research in Darlinghurst, Sydney.
Researchers will be looking at whether the use of semaglutide can improve markers of heart health, as well as metabolic measures such as weight, insulin sensitivity, insulin use and time in range.
What are the befits of participating?
By participating, you’ll learn about your metabolism and receive test results including body composition and energy expenditure measurements. You’ll also be helping to drive advancements in T1D research so that people with the condition have better treatments and quality of life.
There is no cost to participate.
About JDRF’s involvement in this clinical trial
JDRF Australia has funded one of the lead researchers of the trial, Dr Jennifer Snaith, allowing her to undertake this project. Dr Jennifer Snaith is a recipient of JDRF Australia’s Rebecca Davies Fellowship. This funding allows clinicians the opportunity to undertake T1D research alongside their clinical work.
“The JDRF Rebecca Davies Fellowship allows me to undertake the RESET1 study, an essential research project that will examine how a simple once-a-week injection, given in addition to insulin, can address cardiovascular disease in type 1 diabetes. The overall mission of my career and my team is to improve the lives of people living with type 1 diabetes by addressing cardiovascular health. This fellowship helps us greatly in achieving this goal.”
Dr Jennifer Snaith, co-lead of the RESET1 study
Where can I find more information?
For further information about the trial, email RESET1@garvan.org.au or call Dr Ruth Frampton on 0491 731 769.
